Background/Aims: Chemicals that interfere with reactive oxygen species metabolism can act as potential candidates for the treatment of cancer. Some of the glucosides of citrus limonin inhibit the endogenously generated reactive oxygen species. The aim is to study the interactions of limonin with chemotherapy. Methods: Breast cancer cell lines MCF-7 (p53 wild type) and MDA-MB-231 (p53 mutant) as well as the nontumorigenic epithelial cell line MCF-10 were used to screen the effect of limonin at 1-, 5- and 10-µM concentrations with camptothecin for apoptosis and NFĸB, p38 and ERK-MAPK signaling kinase assays. The effect of cyclophosphamide and limonin on MDA MB 231 xenografts was also studied. Results: Our results indicate that limonin did not inhibit camptothecin-induced apoptosis in human breast cancer cells in vitro through noninterference of camptothecin-induced phosphorylation of p38 MAPK and ERK-MAPK. Using an in vivo model of human breast cancer, limonin in combination with cyclophosphamide was not found to inhibit the cyclophosphamide-induced tumor regression through a reduced mitotic index of tumor xenograft cells when compared to treatment with cyclophosphamide alone. Conclusion: Both in vitro and in vivo results suggest that limonin could be beneficial for breast cancer patients undergoing chemotherapy.

1.
Jacob R, Hasegawa S, Manners G: The potential of citrus limonoids as anticancer agents. Perishable Handling Quarterly 2000;102:6–8.
2.
Vanamala J, Leonardi T, Patil BS, Taddeo SS, Murphy ME, Pike LM, Chapkin RS, Lupton JR, Turner ND: Suppression of colon carcinogenesis by bioactive compounds in grapefruit. Carcinogenesis 2006;27:1257–1265.
3.
Poulose SM, Harris ED, Patil BS: Citrus limonoids induce apoptosis in human neuroblastoma cells and have radical scavenging activity. J Nutr 2005;135:870–877.
4.
Breksa AP 3rd, Manners GD: Evaluation of the antioxidant capacity of limonin, nomilin, and limonin glucoside. J Agric Food Chem 2006;54:3827–3831.
5.
Miyagi Y, Om AS, Chee KM, Bennink MR: Inhibition of azoxymethane-induced colon cancer by orange juice. Nutr Cancer 2000;36:224–229.
6.
Kim W, Fan YY, Smith R, Patil B, Jayaprakasha GK, McMurray DN, Chapkin RS: Dietary curcumin and limonin suppress CD4+ T-cell proliferation and interleukin-2 production in mice. J Nutr 2009;139:1042–1048.
7.
Lam LK, Li Y, Hasegawa S: Effects of citrus limonoids on glutathione S-transferase activity in mice. J Agric Food Chem 1989;37:878–880.
8.
Somasundaram S, Edmund NA, Moore DT, Small GW, Shi YY, Orlowski RZ: Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res 2002;62:3868–3875.
9.
Lee SW, Fang L, Igarashi M, Ouchi T, Lu KP, Aaronson SA: Sustained activation of Ras/Raf/mitogen-activated protein kinase cascade by the tumor suppressor p53. Proc Natl Acad Sci USA 2000;97:8302–8305.
10.
Orlowski RZ, Baldwin AS Jr: NF-kappaB as a therapeutic target in cancer. Trends Mol Med 2002;8:385–389.
11.
Small GW, Somasundaram S, Moore DT, Shi YY, Orlowski RZ: Repression of mitogen-activated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their antiapoptotic activation of p44/42-MAPK. J Pharmacol Exp Ther 2003;307:861–869.
12.
Ramaswamy B, Povoski SP, Rhoades C, Allen J, Hauger M, Young D, Burak W, Farrar W, Yee L, Kendra K, Somasundaram S, Orlowski, RZ Shapiro CL: Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer. Breast Cancer Res Treat 2005;93:67–74.
13.
Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S: Rel/NFkappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev 1995;9:2723–2735.
14.
Monks NR, Pardee AB: Targeting the NF-kappaB pathway in estrogen receptor negative MDA-MB-231 breast cancer cells using small inhibitory RNAs. J Cell Biochem 2006;98:221–233.
15.
Sakurai H, Chiba H, Miyoshi H, Sugita T, Toriumi W: IkappaB kinases phophorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain. J Biol Chem 1999;274:30353–30356.
16.
Buss H, Dörrie A, Schmitz ML, Hoffmann E, Resch K, Kracht M: Constitutive and interleukin-1-inducible phosphorylation of p65 NF-ĸB at serine 536 is mediated by multiple protein kinases including IĸB kinase (IKK)-α, IKKβ, IKKε, TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated factor II31-mediated interleukin-8 transcription. J Biol Chem 2004;279:55633–55643.
17.
Schwab RF, Sakurai H: IKKbeta phophorylates p6 at S468 in transactivation domain 2. FASEB J 2005;19:1758–1760.
18.
Park MT, Choi JA, Kim MJ, Um HD, Bae S, Kang CM, Cho CK, Kang S, Chung HY, Lee YS, Lee SJ: Suppression of extracellular signal-related kinase and activation of p38 MAPK are two critical events leading to caspase-8- and mitochondria-mediated cell death in phytosphingosine-treated human cancer cells. J Biol Chem 2003;278:50624–50634.
19.
Somasundaram S, Pearce K, Gunasekera RS, Jayaprakasha GK, Patil B: Differential phosphorylations of NFkB and cell growth of MDA-MB 231 human breast cancer cell line by limonins. Acta Horticulturae 2009;841:151–154.
20.
Mandadi KK, Jayaprakasha GK, Bhat N, Patil BS: Red Mexican grapefruit: a novel source for bioactive limonoids and their antioxidant activity. Z Naturforsch C 2007;62:179–188.
21.
Hendricks CB, Rowinsky EK, Grochow LB, Donehower RC, Kaufmann SH: Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res 1992;52:2268–2278.
22.
Hiraoka W, Vazquez N, Nieves-Neira W, Chanock SJ, Pommier Y: Role of oxygen radicals generated by NADPH oxidase in apoptosis induced in human leukemia cells. J Clin Invest 1998;102:1961–1968.
23.
Kharbanda S, Rubin E, Gunji H, Hinz H, Giovanella B, Pantazis P, Kufe D: Camptothecin and its derivatives induce expression of the c-jun proto-oncogene in human myeloid leukemia cells. Cancer Res 1991;51:6636–6642.
24.
Clarke R, Leonessa F, Brunner N, Thompson EW: In vitro models of breast cancer; in Harris JR, Lippman ME, Morrow M, Hellman S (eds): Diseases of the Breast. Philadelphia, Lippincott-Raven, 1996, p 245–261.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.